» Articles » PMID: 27709474

Identifying the Culprit Lesion in Tumor Induced Hypophosphatemia, the Solution of a Clinical Enigma

Overview
Journal Endocrine
Specialty Endocrinology
Date 2016 Oct 7
PMID 27709474
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor-induced osteomalacia is a rare acquired metabolic bone disorder characterized by isolated renal phosphate wasting due to abnormal tumor production of fibroblast growth factor 23. We report the case of a 59 year old woman referred to our department with a long history of progressive diffuse muscle weakness and pain, generalized bone pains and multiple insufficiency fractures of heels, ankles and hips due to a hypophosphatemic osteomalacia. A fibroblast growth factor 23-producing phosphaturic mesenchymal tumor localized in the left quadriceps femoris muscle was identified 7 years after onset of symptoms. Excision of the tumor resulted in normalization of serum phosphate and fibroblast growth factor 23 levels and in complete resolution of the clinical picture with disappearance of all musculoskeletal symptoms. This case illustrates the diagnostic difficulties in establishing a diagnosis tumor-induced osteomalacia and in identifying the responsible tumor. Our case underscores the clinical need to investigate all patients with persistent musculoskeletal symptoms for hypophosphatemia. A systematic approach is of pivotal importance because early recognition and treatment of the metabolic abnormality can prevent deleterious effects of osteomalacia on the skeleton.

Citing Articles

Phosphaturic mesenchymal tumors: radiological aspects and suggested imaging pathway.

Hussein M, Cafarelli F, Paparella M, Rennie W, Guglielmi G Radiol Med. 2021; 126(12):1609-1618.

PMID: 34453276 PMC: 8702419. DOI: 10.1007/s11547-021-01412-1.


Phosphaturic mesenchymal tumor and related wound problem.

Xiao X, Sun X, Ni P, Huang Y, Xie T Medicine (Baltimore). 2018; 97(40):e12507.

PMID: 30290606 PMC: 6200523. DOI: 10.1097/MD.0000000000012507.


Imaging features of phosphaturic mesenchymal tumors.

Broski S, Folpe A, Wenger D Skeletal Radiol. 2018; 48(1):119-127.

PMID: 29987349 DOI: 10.1007/s00256-018-3014-5.


Idiopathic hypophosphatemic osteomalacia: recurrent pseudofracture of the proximal femur in a 65-year-old man.

Chen Y, Gao Y Endocrine. 2016; 55(2):651-652.

PMID: 27995499 DOI: 10.1007/s12020-016-1205-1.


"Slow and steady wins the race": the importance of perseverance in the management of oncogenic osteomalacia.

Manara M, Sinigaglia L Endocrine. 2016; 57(1):1-2.

PMID: 27900654 DOI: 10.1007/s12020-016-1187-z.

References
1.
Ogose A, Hotta T, Emura I, Hatano H, Inoue Y, Umezu H . Recurrent malignant variant of phosphaturic mesenchymal tumor with oncogenic osteomalacia. Skeletal Radiol. 2001; 30(2):99-103. DOI: 10.1007/s002560000306. View

2.
Weidner N, Santa Cruz D . Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer. 1987; 59(8):1442-54. DOI: 10.1002/1097-0142(19870415)59:8<1442::aid-cncr2820590810>3.0.co;2-q. View

3.
de Beur S, Streeten E, Civelek A, McCarthy E, Uribe L, Marx S . Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet. 2002; 359(9308):761-3. DOI: 10.1016/s0140-6736(02)07846-7. View

4.
. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000; 26(3):345-8. DOI: 10.1038/81664. View

5.
Chong W, Molinolo A, Chen C, Collins M . Tumor-induced osteomalacia. Endocr Relat Cancer. 2011; 18(3):R53-77. PMC: 3433741. DOI: 10.1530/ERC-11-0006. View